Review article: The medical treatment of Crohn's perianal fistulas

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 9, 2004, Pages 953-967

  Schwartz, D A ^a   Herdman, C R ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZATHIOPRINE; CIPROFLOXACIN; CREATININE; CYCLOSPORIN; GRANULOCYTE COLONY STIMULATING FACTOR; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR;

ABSCESS DRAINAGE; ALLERGIC REACTION; ANESTHESIA; ANTIBODY PRODUCTION; ANUS FISTULA; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DIARRHEA; DIET THERAPY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DRUG EFFICACY; ELEMENTAL DIET; ENDOSCOPY; FISTULOGRAPHY; GINGIVA HYPERPLASIA; GLOSSITIS; HEADACHE; HELPER CELL; HIRSUTISM; HUMAN; HYPERBARIC OXYGEN; HYPERTENSION; INCIDENCE; INFECTION; INSOMNIA; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; LUPUS VULGARIS; META ANALYSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATITIS; PARENTERAL NUTRITION; PATHOGENESIS; PERIANAL ABSCESS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROCTITIS; RASH; RELAPSE; REMISSION; REVIEW; RISK ASSESSMENT; SEIZURE; SENSORY NEUROPATHY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SUPPOSITORY; TASTE; TASTE DISORDER; TOTAL PARENTERAL NUTRITION; TOXIC HEPATITIS; TREMOR; TUBERCULOSIS; ULTRASOUND;

ANTI-BACTERIAL AGENTS; ANUS DISEASES; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PROCTITIS; RECTAL FISTULA; TREATMENT OUTCOME;

EID: 2442661318     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01917.x     Document Type: Review

References (128)

1. Levien DH, Surrell J, Mazier WP. Surgical treatment of anorectal fistula in patients with Crohn's disease. Surg Gynecol Obstet 1989; 169(2): 133-6.
2. Williams JG, Rothenberger DA, Nemer FD, Goldberg SM. Fistula-in-ano in Crohn's disease. Results of aggressive surgical treatment. Dis Colon Rectum 1991; 34(5): 378-84.
3. Wolff BG, Culp CE, Beart RW Jr, Ilstrup DM, Ready RL. Anorectal Crohn's disease. A long-term perspective. Dis Colon Rectum 1985; 28(10): 709-11.
4. Bannister L, ed. Alimentary System. Vol. 38. New York: Churchill Livingstone, 1995.
5. Parks A. The pathogenesis and treatment of fistula-in-ano. Br Med J 1961; 1: 463-9.
6. Goligher J. Fistulo-in-ano. In: Goligher J, ed. Surgery of the Anus, Rectum and Colon, 5th edn. London: Bailliere Tindall, 1984: 178-220.
7. Hughes L. Surgical pathology and management of anorectal Crohn's disease. J R Soc Med 1978; 71: 644-51.
8. Hughes LE. Clinical classification of perianal Crohn's disease. Dis Colon Rectum 1992; 35(10): 928-32.
9. Parks AG, Gordon PH, Hardcastle JD. A classification of fistula-in-ano. Br J Surg 1976; 63(1): 1-12.
10. American Gastroenterological Association. American Gastroenterological Association medical position statement: perianal Crohn's disease. Gastroenterology 2003; 125(5): 1503-7.
11. Bell SJ, Williams AB, Wiesel P, Wilkinson K, Cohen RC, Kamm MA. The clinical course of fistulating Crohn's disease. Aliment Pharmacol Ther 2003; 17(9): 1145-51.
12. Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 2003; 9(2): 98-103.
13. Scott HJ, Northover JM. Evaluation of surgery for perianal Crohn's fistulas. Dis Colon Rectum 1996; 39(9): 1039-43.
14. Topstad DR, Panaccione R, Heine JA, Johnson DR, MacLean AR, Buie WD. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience. Dis Colon Rectum 2003; 46(5): 577-83.
15. Hawley PR. Anorectal fistula. Clin Gastroenterol 1975; 4(3): 635-49.
16. Vasilevsky C, Stein B. Fistula-in-ano. In: Wexner S, Vernava A, eds. Clinical Decision Making in Colorectal Surgery. New York: Igaku-Shoin. 1995: 137-41.
17. Hellers G, Bergstrand O, Ewerth S, Holmstrom B. Occurrence and outcome after primary treatment of anal fistulae in Crohn's disease. Gut 1980; 21: 525-7.
18. Rankin GB, Watts HD, Melnyk CS, Kelley ML Jr. National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology 1979; 77(4 Part 2): 914-20.
19. Farmer R, Hawk W, Turnbull RJ. Clinical patterns in Crohn's disease. A statistical study of 615 cases. Gastroenterology 1975; 68: 627-35.
20. Williams DR, Coller JA, Corman ML, Nugent FW, Veidenheimer MC. Anal complications in Crohn's disease. Dis Colon Rectum 1981; 24(1): 22-41.
21. Buchmann P, Keighley MR, Allan RN, Thompson H. Alexander-Williams J. Natural history of perianal Crohn's disease. Ten year follow-up: a plea for conservatism. Am J Surg 1980; 140(5): 642-4.
22. Greenstein AJ, Kark AE, Dreiling DA. Crohn's disease of the colon. I. Fistula in Crohn's disease of the colon, classification presenting features and management in 63 patients. Am J Gastroenterol 1974; 62(5): 419-29.
23. Hobbiss JH, Schofield PF. Management of perianal Crohn's disease. J R Soc Med 1982; 75(6): 414-7.
24. van Donegn LM, Lubbers E. Perianal fistulas in patients with Crohn's disease. Arch Surg 1986; 121: 1187-90.
25. Goebell H. Perianal complications in Crohn's disease. Neth J Med 1990; 37(Suppl. 1): S47-51.
26. Fielding JF. Perianal lesions in Crohn's disease. J R Coll Surgeons Edinb 1972; 17(1): 32-7.
27. Marks CG, Ritchie JK, Lockhart-Mummery HE. Anal fistulas in Crohn's disease. Br J Surg 1981; 68(8): 525-7.
28. Schwartz D, Loftus E, Tremaine W, Panaccione R, Sandborn W. The natural history of fistulizing Crohn's disease: a population based study. Gastroenterology 2000; 118(4): A337(Abstract).
29. Garrett JW, Drossman DA. Health status in inflammatory bowel disease. Biological and behavioral considerations. Gastroenterology 1990; 99(1): 90-6.
30. Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995; 20(1): 27-32.
31. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340(18): 1398-405.
32. Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther 2003; 18(11-12): 1113-20.
33. Rasul I, Wilson S, Cohen Z, Greenberg G. Infliximab therapy for Crohn's disease fistulae: discordance between perianal ultrasound findings and clinical response. Gastroenterology 2001; 120: A619(Abstract).
34. Van Assche G, Vanbeckevoort D, Bielen D, et al. Persistent fistula tracks in perianal Crohn's disease after long term infliximab treatment: correlation with clinical outcome. Gastroenterology 2003; 124(Suppl. 1): A3(Abstract).
35. Van Assche G, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol 2003; 98(2): 332-9.
36. Van Bodegraven A, Sloots C, Felt-Bersma R, Meuwissen S. Endosonographic evidence of persistence of Crohn's disease associated fistulas after infliximab treatment, irrespective of clinical response. Dis Colon Rectum 2002; 45: 39-46.
37. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002; 122(2): 512-30.
38. Makowiec F, Jehle EC, Becker HD, Starlinger M. Perianal abscess in Crohn's disease. Dis Colon Rectum 1997; 40(4): 443-50.
39. Williamson PR, Hellinger MD, Larach SW, Ferrara A. Twenty-year review of the surgical management of perianal Crohn's disease. Dis Colon Rectum 1995; 38(4): 389-92.
40. Fuhrman GM, Larach SW. Experience with perirectal fistulas in patients with Crohn's disease. Dis Colon Rectum 1989; 32(10): 847-8.
41. Sohn N, Korelitz BI, Weinstein MA. Anorectal Crohn's disease: definitive surgery for fistulas and recurrent abscesses. Am J Surg 1980; 139(3): 394-7.
42. Bayer I, Gordon PH. Selected operative management of fistula-in-ano in Crohn's disease. Dis Colon Rectum 1994; 37(8): 760-5.
43. Halme L, Sainio AP. Factors related to frequency, type, and outcome of anal fistulas in Crohn's disease. Dis Colon Rectum 1995; 38(1): 55-9.
44. Van Beers B, Grandin C, Kartheuser A, et al. MRI of complicated anal fistulae: comparison with digital examination. J Comput Assist Tomogr 1994; 18(1): 87-90.
45. Glass RE, Ritchie JK, Lennard-Jones JE, Hawley PR, Todd IP. Internal fistulas in Crohn's disease. Dis Colon Rectum 1985; 28(8): 557-61.
46. Fazio VW, Wilk P, Turnbull RB Jr, Jagelman DG. The dilemma of Crohn's disease: ileosigmoidal fistula complicating Crohn's disease. Dis Colon Rectum 1977; 20(5): 381-6.
47. Kuijpers HC, Schulpen T. Fistulography for fistula-in-ano. Is it useful? Dis Colon Rectum 1985; 28(2): 103-4.
48. Pomerri F, Pittarello F, Dodi G, Pianon P, Muzzio PC. [Radiologic diagnosis of anal fistulae with radio-opaque markers]. Radiologia Med 1988; 75(6): 632-7.
49. Weisman RI, Orsay CP, Pearl RK, Abcarian H. The role of fistulography in fistula-in-ano. Report of five cases. Dis Colon Rectum 1991; 34(2): 181-4.
50. Schratter-Sehn AU, Lochs H, Vogelsang H, Schurawitzki H, Herold C, Schratter M. Endoscopic ultrasonography versus computed tomography in the differential diagnosis of perianorectal complications in Crohn's disease. Endoscopy 1993; 25(9): 582-6.
51. Van Outryve MJ, Pelckmans PA, Michielsen PP, Van Maercke YM. Value of transrectal ultrasonography in Crohn's disease. Gastroenterology 1991; 101(5): 1171-7.
52. Fishman EK, Wolf EJ, Jones B, Bayless TM, Siegelman SS. CT evaluation of Crohn's disease: effect on patient management. Am J Roentgenol 1987; 148(3): 537-40.
53. Berliner L, Redmond P, Purow E, Megna D, Sottile V. Computed tomography in Crohn's disease. Am J Gastroenterol 1982; 77(8): 548-53.
54. Yousem DM, Fishman EK, Jones B. Crohn disease: perirectal and perianal findings at CT. Radiology 1988; 167(2): 331-4.
55. Goldberg HI, Gore RM, Margulis AR, Moss AA, Baker EL. Computed tomography in the evaluation of Crohn disease. Am J Roentgenol 1983; 140(2): 277-82.
56. Kerber GW, Greenberg M, Rubin JM. Computed tomography evaluation of local and extraintestinal complications of Crohn's disease. Gastrointest Radiol 1984; 9(2): 143-8.
57. Lunniss PJ, Barker PG, Sultan AH, et al. Magnetic resonance imaging of fistula-in-ano. Dis Colon Rectum 1994; 37(7): 708-18.
58. Barker PG, Lunniss PJ, Armstrong P, Reznek RH, Cottam K, Phillips RK. Magnetic resonance imaging of fistula-in-ano: technique, interpretation and accuracy. Clin Radiol 1994; 49(1): 7-13.
59. Haggett PJ, Moore NR, Shearman JD, Travis SP, Jewell DP, Mortensen NJ. Pelvic and perineal complications of Crohn's disease: assessment using magnetic resonance imaging. Gut 1995; 36(3): 407-10.
60. Spencer JA, Chapple K, Wilson D, Ward J, Windsor AC, Ambrose NS. Outcome after surgery for perianal fistula: predictive value of MR imaging. Am J Roentgenol 1998; 171(2): 403-6.
61. Koelbel G, Schmiedl U, Majer MC, et al. Diagnosis of fistulae and sinus tracts in patients with Crohn disease: value of MR imaging. Am J Roentgenol 1989; 152(5): 999-1003.
62. Tio TL, Mulder CJ, Wijers OB, Sars PR, Tytgat GN. Endosonography of peri-anal and peri-colorectal fistula and/or abscess in Crohn's disease. Gastrointest Endosc 1990; 36(4): 331-6.
63. Mulder C, Tio T, Tytgat G. Transrectal ultrasonography in the assessment of perianal fistula and/or abscess in Crohn's disease. Gastroenterology 1988; 94: A313(Abstract).
64. Orsoni P, Barthet M, Portier F, Panuel M, Desjeux A, Grimaud JC. Prospective comparison of endosonography, magnetic resonance imaging and surgical findings in anorectal fistula and abscess complicating Crohn's disease. Br J Surg 1999; 86(3): 360-4.
65. Schwartz DA, Wiersema MJ, Dudiak KM, et al. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas. Gastroenterology 2001; 121(5): 1064-72.
66. Bell SJ, Halligan S, Windsor AC, Williams AB, Wiesel P, Kamm MA. Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2003; 17(3): 387-93.
67. Ursing B, Kamme C. Metronidazole for Crohn's disease. Lancet 1975; 1: 775-7.
68. Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn's disease with metronidazole. Gastroenterology 1980; 79(2): 357-65.
69. Schneider MU, Strobel S, Riemann JF, Demling L. [Treatment of Crohn's disease with metronidazole (author's translation)]. Dtsch Med Wochenschrift 1981; 106(36): 1126-9.
70. Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol 1984; 79(7): 533-40.
71. Schneider MU, Laudage G, Guggenmoos-Holzmann I, Riemann JF. [Metronidazole in the treatment of Crohn's disease: results of a controlled randomized prospective study]. Dtsch Med Wochenschrift 1985; 110(45): 1724-30.
72. Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 1982; 83(2): 383-7.
73. Peppercorn MA. Is there a role for antibiotics as primary therapy in Crohn's ileitis? J Clin Gastroenterol 1993; 17(3): 235-7.
74. Turunen U, Farkkila M, Valtonen V. Long-term outcome of ciprofloxacin treatment in severe perianal or fistulous Crohn's disease. Gastroenterology 1993; 104: A793 (Abstract).
75. Klein M, Binder HJ, Mitchell M, Aaronson R, Spiro H. Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology 1974; 66(5): 916-22.
76. Rosenberg JL, Levin B, Wall AJ, Kirsner JB. A controlled trial of azathioprine in Crohn's disease. Am J Digest Dis 1975; 20(8): 721-6.
77. Rhodes J, Bainton D, Beck P, Campbell H. Controlled trial of azathioprine in Crohn's disease. Lancet 1971; 2(7737): 1273-6.
78. Willoughby JM, Beckett J, Kumar PJ, Dawson AM. Controlled trial of azathioprine in Crohn's disease. Lancet 1971; 2(7731): 944-7.
79. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302(18): 981-7.
80. Pearson D, May G, Fick G, Sutherland L. Azathioprine and 6-mercaptopurine in Crohn disease: a meta analysis. Ann Intern Med 1995; 123: 132-42.
81. Korelitz BI, Present DH. Favorable effect of mercaptopurine on fistulae of Crohn's disease. Digest Dis Sci 1985; 30(1): 58-64.
82. Jeshion WC, Larsen KL, Jawad AF, et al. Azathioprine and 6-mercaptopurine for the treatment of perianal Crohn's disease in children. J Clin Gastroenterol 2000; 30(3): 294-8.
83. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111(8): 641-9.
84. Fukushima T, Sugita A, Masuzawa S, Yamazaki Y. Effect of cyclosporine A on active Crohn's disease. Gastroenterol Jpn 1989; 24(1): 12-5.
85. Lichtiger S. Cyclosporine therapy in inflammatory bowel disease: open-label experience. Mount Sinai J Med 1990; 57(5): 315-9.
86. Hanauer SB, Smith MB. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A. Am J Gastroenterol 1993; 88(5): 646-9.
87. Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Digest Dis Sci 1994; 39(2): 374-80.
88. Markowitz J, Rosa J, Grancher K, Aiges H, Daum F. Long-term mercaptopurine treatment in adolescents with Crohn's disease. Gastroenterology 1990; 99(5): 1347-51.
89. Abreu-Martin M, Vasiliauskas E, Gaiennie J. Continuous infusion cyclosporine ineffective for severe acute Crohn's disease... but for how long? Gastroenterology 1996; 110: A851(Abstract).
90. O'Neill J, Pathmakanthan S, Goh J. Cyclosporine A induces remission in fistulous Crohn's disease but relapse occurs upon cessation of treatment. Gastronterology 1997; 112: A1056(Abstract).
91. Hinterleitner TA, Petritsch W, Aichbichler B, Fickert P, Ranner G, Krejs GJ. Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn's disease. Z Gastroenterol 1997; 35(8): 603-8.
92. Egan LJ, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Am J Gastroenterol 1998; 93(3): 442-8.
93. Gurudu SR, Griffel LH, Gialanella RJ, Das KM. Cyclosporine therapy in inflammatory bowel disease: short-term and long-term results. J Clin Gastroenterol 1999; 29(2): 151-4.
94. Sandborn WJ. Cyclosporine therapy for inflammatory bowel disease: definitive answers and remaining questions [editorial]. Gastroenterology 1995; 109(3): 1001-3.
95. Sandborn W. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995; 1: 48-63.
96. Lowry P, Weaver A, Tremaine W, Sandborn W. Combination therapy with oral tacrolimus (FK506) and azathioprine or mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. Inflamm Bowel Dis 1999; 5(4): 239-45.
97. Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am J Gastroenterol 1997; 92(5): 876-9.
98. Fellermann K, Ludwig D, Stahl M, David-Walek T, Stange EF. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol 1998; 93(10): 1860-6.
99. Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 2003; 125(2): 380-8.
100. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999; 5(2): 119-33.
101. Sands B, Van Deventer S, Bernstein C. Long-term treatment of fistulizing Crohn's disease: response to infliximab in ACCENT II trials through 54 weeks. Gastroenterology 2002; 122: A81(Abstract).
102. Ochsenkuhn T, Goke B, Sackmann M. Combining infliximab with mercaptopurine/azathioprine for fistula therapy in Crohn's disease. Am J Gastroenterol 2002; 97(8): 2022-5.
103. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348(7): 601-8.
104. Hanauer S. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther 1999; 13(Suppl. 4): 16-22.
105. Areseau KO, Cohn SM, Cominelli F, Connors AF Jr. Cost-utility of initial medical management for Crohn's disease perianal fistulae. Gastroenterology 2001; 120: 1640-56.
106. Voitk AJ, Echave V, Brown RA, Gurd FN. Use of elemental diet during the adaptive stage of short gut syndrome. Gastroenterology 1973; 65(3): 419-26.
107. Segal AW, Levi AJ, Loewi G. Levamisole in the treatment of Crohn's disease. Lancet 1977; 2(8034): 382-5.
108. Axelsson C, Jarnum S. Assessment of the therapeutic value of an elemental diet in chronic inflammatory bowel disease. Scand J Gastroenterol 1977; 12(1): 89-95.
109. Russell RI, Hall MJ. Elemental diet therapy in the management of complicated Crohn's disease. Scottish Med J 1979; 24(4): 291-5.
110. Teahon K, Bjarnason I, Pearson M, Levi AJ. Ten years' experience with an elemental diet in the management of Crohn's disease. Gut 1990; 31(10): 1133-7.
111. Jones VA. Comparison of total parenteral nutrition and elemental diet in induction of remission of Crohn's disease. Long-term maintenance of remission by personalized food exclusion diets. Digest Dis Sci 1987; 32(12 Suppl.): 100S-107S.
112. Fukuda Y, Kosaka T, Okui M, Hirakawa H, Shimoyama T. Efficacy of nutritional therapy for active Crohn's disease. J Gastroenterol 1995; 30(Suppl. 8): 83-7.
113. Milewski PJ, Irving MH. Parenteral nutrition in Crohn's disease. Dis Colon Rectum 1980; 23(6): 395-400.
114. Harford FJ Jr, Fazio VW. Total parenteral nutrition as primary therapy for inflammatory disease of the bowel. Dis Colon Rectum 1978; 21(8): 555-7.
115. Greenberg GR, Fleming CR, Jeejeebhoy KN, Rosenberg IH, Sales D, Tremaine WJ. Controlled trial of bowel rest and nutritional support in the management of Crohn's disease. Gut 1988; 29(10): 1309-15.
116. Calam J, Crooks PE, Walker RJ. Elemental diets in the management of Crohn's perianal fistulae. J Parenteral Enteral Nutr 1980; 4(1): 4-8.
117. Horgan K. Initial experience with mycophenolate mofetil in the treatment of severe inflammatory bowel disease. Gastroenterology 1997; 112(Suppl.): A999(Abstract).
118. Fickert P, Hinterleitner TA, Wenzl HH, Aichbichler BW, Petritsch W. Mycophenolate mofetil in patients with Crohn's disease. Am J Gastroenterol 1998; 93(12): 2529-32.
119. Mahadevan U, Marion J, Present D. The place of methotrexate in the treatment of refractory Crohn's disease. Gastroenterology 1997; 112(Suppl.): A1031(Abstract).
120. Vasiliauskas E, Kam L, Abreu-Martin M, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroeneterology 1999; 117: 1278-87.
121. Ehrenpreis E, Kane S, Cohen L, Cohen R. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroeneterology 1999; 117: 127-7.
122. Vaughan D, Drumm B. Treatment of fistulas with granulocyte colony-stimulating factor in a patient with Crohn's disease [letter]. N Engl J Med 1999; 340(3): 239-40.
123. Brady CEd, Cooley BJ, Davis JC. Healing of severe perineal and cutaneous Crohn's disease with hyperbaric oxygen. Gastroenterology 1989; 97(3): 756-60.
124. Brady CEd. Hyperbaric oxygen and perineal Crohn's disease: a follow-up [letter]. Gastroenterology 1993; 105(4): 1264.
125. Nelson EW Jr, Bright DE, Villar LF. Closure of refractory perineal Crohn's lesion. Integration of hyperbaric oxygen into case management. Digest Dis Sci 1990; 35(12): 1561-5.
126. Lavy A, Weisz G, Adir Y, Ramon Y, Melamed Y, Eidelman S. Hyperbaric oxygen for perianal Crohn's disease. J Clin Gastroenterol 1994; 19(3): 202-5.
127. Colombel JF, Mathieu D, Bouault JM, et al. Hyperbaric oxygenation in severe perineal Crohn's disease. Dis Colon Rectum 1995; 38(6): 609-14.
128. Poritz LS, Rowe WA, Koltun WA. Remicade does not abolish the need for surgery in fistulizing Crohn's disease. Dis Colon Rectum 2002; 45(6): 771-5.